Ifakara Health Institute, Ifakara, United Republic of Tanzania, Off Mlabani Passage, P. O Box 53, Ifakara, Tanzania.
St Francis Referral Hospital, Ifakara, United Republic of Tanzania.
BMC Infect Dis. 2020 May 15;20(1):349. doi: 10.1186/s12879-020-05073-9.
Patients with clinically suspected tuberculosis are often treated empirically, as diagnosis - especially of extrapulmonary tuberculosis - remains challenging. This leads to an overtreatment of tuberculosis and to underdiagnosis of possible differential diagnoses.
This open-label, parallel-group, superiority randomized controlled trial is done in a rural and an urban center in Tanzania. HIV-positive and -negative adults (≥18 years) with clinically suspected extrapulmonary tuberculosis are randomized in a 1:1 ratio to an intervention- or control group, stratified by center and HIV status. The intervention consists of a management algorithm including extended focused assessment of sonography for HIV and tuberculosis (eFASH) in combination with chest X-ray and microbiological tests. Treatment with anti-tuberculosis drugs is started, if eFASH is positive, chest X-ray suggests tuberculosis, or a microbiological result is positive for tuberculosis. Patients in the control group are managed according national guidelines. Treatment is started if microbiology is positive or empirically according to the treating physician. The primary outcome is the proportion of correctly managed patients at 6 months (i.e patients who were treated with anti-tuberculosis treatment and had definite or probable tuberculosis, and patients who were not treated with anti-tuberculosis treatment and did not have tuberculosis). Secondary outcomes are the proportion of symptom-free patients at two and 6 months, and time to death. The sample size is 650 patients.
This study will determine, whether ultrasound in combination with other tests can increase the proportion of correctly managed patients with clinically suspected extrapulmonary tuberculosis, thus reducing overtreatment with anti-tuberculosis drugs.
PACTR, Registration number: PACTR201712002829221, registered December 1st 2017.
由于诊断(尤其是肺外结核病的诊断)仍然具有挑战性,因此临床上疑似结核病的患者通常会接受经验性治疗。这导致结核病过度治疗和可能的鉴别诊断漏诊。
这是一项在坦桑尼亚农村和城市中心进行的开放性、平行组、优效性随机对照试验。将临床上疑似肺外结核病的 HIV 阳性和阴性成人(≥18 岁)按 1:1 比例随机分为干预组或对照组,按中心和 HIV 状态分层。干预措施包括包括扩展焦点超声评估 HIV 和结核病(eFASH),联合胸部 X 光和微生物学检查的管理算法。如果 eFASH 阳性、胸部 X 光提示结核病或微生物学结果阳性提示结核病,则给予抗结核药物治疗。对照组患者根据国家指南进行管理。如果微生物学阳性或根据治疗医生的经验进行经验性治疗,则开始治疗。主要结局是 6 个月时正确管理患者的比例(即接受抗结核治疗且患有明确或可能结核病的患者,以及未接受抗结核治疗且未患有结核病的患者)。次要结局是 2 个月和 6 个月时无症状患者的比例以及死亡时间。样本量为 650 例患者。
本研究将确定超声联合其他检查是否可以增加临床上疑似肺外结核病患者正确管理的比例,从而减少抗结核药物的过度治疗。
PACTR,注册号:PACTR201712002829221,注册日期 2017 年 12 月 1 日。